FTase (Farnesyltransferase) inhibitor– Pipeline Insight, 2021
This report can be delivered to the clients within 48 hrs
DelveInsight’s, “FTase (Farnesyltransferase) inhibitor– Pipeline Insight, 2021,” report provides comprehensive insights about 2+ companies and 2+ pipeline drugs in FTase inhibitor pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.
Geography Covered
FTase inhibitor: Overview
Farnesyltransferase (FTase) is a heterodimeric zinc enzyme that belongs to the transferases family. It catalyzes the synthesis of geranylgeranyl diphosphate from Trans, trans-farnesyl diphosphate and isopentenyl diphosphate. Protein farnesyltransferase (FTase) is a two-subunit enzyme that is comprised by a 48 kDa ?-subunit and a 46 kDa ?-subunit.
FTase catalyzes the post-translational addition of a hydrophobic isoprenoid farnesyl moiety from farnesyl diphosphate (FPP), to a cysteine residue of a protein substrate containing a typical CAAX motif at the carboxyl terminus.
FTase Inhibitors- Farnesyltransferase inhibitors hold considerable promise as anticancer drugs in the clinical studies. Several studies evaluated including the identification of natural products such as the chaetomellic and zaragozic acids that mimic farnesylpyrophosphate, bisubstrate transition state analogs combining elements of the farnesyl and tetrapeptide substrates and peptidomimetics that reproduce features of the carboxyl terminal tetrapeptide CA1A2X sequence. Several farnesyl transferase inhibitors are in clinical development for the treatment of solid tumors.
FTase inhibitor Emerging Drugs Chapters
This segment of the FTase inhibitor report encloses its detailed analysis of various drugs in different stages of clinical development, including phase III, II, I, preclinical and Discovery. It also helps to understand clinical trial details, expressive pharmacological action, agreements and collaborations, and the latest news and press releases.
FTase inhibitor Emerging Drugs
Further product details are provided in the report……..
FTase inhibitor: Therapeutic Assessment
This segment of the report provides insights about the different FTase inhibitor drugs segregated based on following parameters that define the scope of the report, such as:
FTase inhibitor: Pipeline Development Activities
The report provides insights into different therapeutic candidates in phase II, I, preclinical and discovery stage. It also analyses FTase inhibitor therapeutic drugs key players involved in developing key drugs.
Pipeline Development Activities
The report covers the detailed information of collaborations, acquisition and merger, licensing along with a thorough therapeutic assessment of emerging FTase inhibitor drugs.
Report Highlights
Current Scenario and Emerging Therapies:
DelveInsight’s, “FTase (Farnesyltransferase) inhibitor– Pipeline Insight, 2021,” report provides comprehensive insights about 2+ companies and 2+ pipeline drugs in FTase inhibitor pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.
Geography Covered
- Global coverage
FTase inhibitor: Overview
Farnesyltransferase (FTase) is a heterodimeric zinc enzyme that belongs to the transferases family. It catalyzes the synthesis of geranylgeranyl diphosphate from Trans, trans-farnesyl diphosphate and isopentenyl diphosphate. Protein farnesyltransferase (FTase) is a two-subunit enzyme that is comprised by a 48 kDa ?-subunit and a 46 kDa ?-subunit.
FTase catalyzes the post-translational addition of a hydrophobic isoprenoid farnesyl moiety from farnesyl diphosphate (FPP), to a cysteine residue of a protein substrate containing a typical CAAX motif at the carboxyl terminus.
FTase Inhibitors- Farnesyltransferase inhibitors hold considerable promise as anticancer drugs in the clinical studies. Several studies evaluated including the identification of natural products such as the chaetomellic and zaragozic acids that mimic farnesylpyrophosphate, bisubstrate transition state analogs combining elements of the farnesyl and tetrapeptide substrates and peptidomimetics that reproduce features of the carboxyl terminal tetrapeptide CA1A2X sequence. Several farnesyl transferase inhibitors are in clinical development for the treatment of solid tumors.
FTase inhibitor Emerging Drugs Chapters
This segment of the FTase inhibitor report encloses its detailed analysis of various drugs in different stages of clinical development, including phase III, II, I, preclinical and Discovery. It also helps to understand clinical trial details, expressive pharmacological action, agreements and collaborations, and the latest news and press releases.
FTase inhibitor Emerging Drugs
- Tipifarnib: Kura Oncology
- Lonafarnib: Eiger Biopharmaceuticals
Further product details are provided in the report……..
FTase inhibitor: Therapeutic Assessment
This segment of the report provides insights about the different FTase inhibitor drugs segregated based on following parameters that define the scope of the report, such as:
- Major Players working on FTase inhibitor
- Phases
- Late-stage products (Phase III and
- Mid-stage products (Phase II and
- Early-stage products (Phase I/II and Phase I) along with the details of
- Pre-clinical and Discovery stage candidates
- Discontinued & Inactive candidates
- Route of Administration
- Infusion
- Intradermal
- Intramuscular
- Intranasal
- Intravaginal
- Oral
- Parenteral
- Subcutaneous
- Topical.
- Molecule Type
- Vaccines
- Monoclonal Antibody
- Peptides
- Polymer
- Small molecule
- Product Type
FTase inhibitor: Pipeline Development Activities
The report provides insights into different therapeutic candidates in phase II, I, preclinical and discovery stage. It also analyses FTase inhibitor therapeutic drugs key players involved in developing key drugs.
Pipeline Development Activities
The report covers the detailed information of collaborations, acquisition and merger, licensing along with a thorough therapeutic assessment of emerging FTase inhibitor drugs.
Report Highlights
- The companies and academics are working to assess challenges and seek opportunities that could influence FTase inhibitor R&D. The therapies under development are focused on novel approaches for FTase inhibitor.
- FTASE inhibitor Pipeline Analysis
- Therapeutic Assessment
- Unmet Needs
- Impact of Drugs
- Pipeline Product Profiles
- Therapeutic Assessment
- Pipeline Assessment
- Inactive drugs assessment
- Unmet Needs
Current Scenario and Emerging Therapies:
- How many companies are developing FTase inhibitor drugs?
- How many FTase inhibitor drugs are developed by each company?
- How many emerging drugs are in mid-stage, and late-stage of development for FTase inhibitor?
- What are the key collaborations (Industry–Industry, Industry–Academia), Mergers and acquisitions, licensing activities related to the FTase inhibitor therapeutics?
- What are the recent trends, drug types and novel technologies developed to overcome the limitation of existing therapies?
- What are the clinical studies going on for FTase inhibitor and their status?
- What are the key designations that have been granted to the emerging drugs?
- Kura Oncology
- Eiger Biopharmaceuticals
- Tipifarnib
- Lonafarnib
Introduction
Executive Summary
FTASE inhibitor: Overview
Structure
Mechanism of Action
Pipeline Therapeutics
Comparative Analysis
Therapeutic Assessment
Assessment by Product Type
Assessment by Stage and Product Type
Assessment by Route of Administration
Assessment by Stage and Route of Administration
Assessment by Molecule Type
Assessment by Stage and Molecule Type
FTASE inhibitor – DelveInsight’s Analytical Perspective
In-depth Commercial Assessment
FTASE inhibitor companies’ collaborations, Licensing, Acquisition -Deal Value Trends
FTASE inhibitor Collaboration Deals
Company-Company Collaborations (Licensing / Partnering) Analysis
Company-University Collaborations (Licensing / Partnering) Analysis
Late Stage Products (Phase III)
Comparative Analysis
Tipifarnib: Kura Oncology
Product Description
Research and Development
Product Development Activities
Drug profiles in the detailed report
Mid Stage Products (Phase II)
Comparative Analysis
Drug name: Company name
Product Description
Research and Development
Product Development Activities
Drug profiles in the detailed report
Early Stage Products (Phase I)
Comparative Analysis
Drug name: Company name
Product Description
Research and Development
Product Development Activities
Drug profiles in the detailed report
Pre-clinical and Discovery Stage Products
Comparative Analysis
Drug name: Company name
Product Description
Research and Development
Product Development Activities
Drug profiles in the detailed report
Inactive Products
Comparative Analysis
FTase inhibitor Key Companies
FTase inhibitor Key Products
FTase inhibitor- Unmet Needs
FTase inhibitor- Market Drivers and Barriers
FTase inhibitor- Future Perspectives and Conclusion
FTase inhibitor Analyst Views
FTase inhibitor Key Companies
Appendix
Executive Summary
FTASE inhibitor: Overview
Structure
Mechanism of Action
Pipeline Therapeutics
Comparative Analysis
Therapeutic Assessment
Assessment by Product Type
Assessment by Stage and Product Type
Assessment by Route of Administration
Assessment by Stage and Route of Administration
Assessment by Molecule Type
Assessment by Stage and Molecule Type
FTASE inhibitor – DelveInsight’s Analytical Perspective
In-depth Commercial Assessment
FTASE inhibitor companies’ collaborations, Licensing, Acquisition -Deal Value Trends
FTASE inhibitor Collaboration Deals
Company-Company Collaborations (Licensing / Partnering) Analysis
Company-University Collaborations (Licensing / Partnering) Analysis
Late Stage Products (Phase III)
Comparative Analysis
Tipifarnib: Kura Oncology
Product Description
Research and Development
Product Development Activities
Drug profiles in the detailed report
Mid Stage Products (Phase II)
Comparative Analysis
Drug name: Company name
Product Description
Research and Development
Product Development Activities
Drug profiles in the detailed report
Early Stage Products (Phase I)
Comparative Analysis
Drug name: Company name
Product Description
Research and Development
Product Development Activities
Drug profiles in the detailed report
Pre-clinical and Discovery Stage Products
Comparative Analysis
Drug name: Company name
Product Description
Research and Development
Product Development Activities
Drug profiles in the detailed report
Inactive Products
Comparative Analysis
FTase inhibitor Key Companies
FTase inhibitor Key Products
FTase inhibitor- Unmet Needs
FTase inhibitor- Market Drivers and Barriers
FTase inhibitor- Future Perspectives and Conclusion
FTase inhibitor Analyst Views
FTase inhibitor Key Companies
Appendix
LIST OF TABLES
Table 1 Total Products for FTase inhibitor
Table 2 Late Stage Products
Table 3 Mid Stage Products
Table 4 Early Stage Products
Table 5 Pre-clinical & Discovery Stage Products
Table 6 Assessment by Product Type
Table 7 Assessment by Stage and Product Type
Table 8 Assessment by Route of Administration
Table 9 Assessment by Stage and Route of Administration
Table 10 Assessment by Molecule Type
Table 11 Assessment by Stage and Molecule Type
Table 12 Inactive Products
Table 1 Total Products for FTase inhibitor
Table 2 Late Stage Products
Table 3 Mid Stage Products
Table 4 Early Stage Products
Table 5 Pre-clinical & Discovery Stage Products
Table 6 Assessment by Product Type
Table 7 Assessment by Stage and Product Type
Table 8 Assessment by Route of Administration
Table 9 Assessment by Stage and Route of Administration
Table 10 Assessment by Molecule Type
Table 11 Assessment by Stage and Molecule Type
Table 12 Inactive Products
LIST OF FIGURES
Figure 1 Total Products for FTase inhibitor
Figure 2 Late Stage Products
Figure 3 Mid Stage Products
Figure 4 Early Stage Products
Figure 5 Preclinical and Discovery Stage Products
Figure 6 Assessment by Product Type
Figure 7 Assessment by Stage and Product Type
Figure 8 Assessment by Route of Administration
Figure 9 Assessment by Stage and Route of Administration
Figure 10 Assessment by Molecule Type
Figure 11 Assessment by Stage and Molecule Type
Figure 12 Inactive Products
Figure 1 Total Products for FTase inhibitor
Figure 2 Late Stage Products
Figure 3 Mid Stage Products
Figure 4 Early Stage Products
Figure 5 Preclinical and Discovery Stage Products
Figure 6 Assessment by Product Type
Figure 7 Assessment by Stage and Product Type
Figure 8 Assessment by Route of Administration
Figure 9 Assessment by Stage and Route of Administration
Figure 10 Assessment by Molecule Type
Figure 11 Assessment by Stage and Molecule Type
Figure 12 Inactive Products
